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ABSTRACT:
26 Prediction is essential for motor function in everyday life. For instance, 27 predictive mechanisms improve the perception of a moving target by increasing eye 28 speed anticipatively, thus reducing motion blur on the retina. Subregions of the 29 frontal lobes play a key role in eye movements in general and in smooth pursuit in 30 particular but their precise function is not firmly established. Here, the role of frontal 31 lobes in the timing of predictive action is demonstrated by studying predictive smooth 32 pursuit during transient blanking of a moving target in mild frontotemporal lobar 33 degeneration (FTLD) and Alzheimer's disease (AD) patients. While control subjects 34 and AD patients predictively reaccelerated their eyes before the predicted time of 35 target reappearance, FTLD patients did not. The difference was so dramatic 36 (classification accuracy > 90%) that it could even lead to the definition of a new 37 biomarker. In contrast, anticipatory eye movements triggered by the disappearance 38 of the fixation point were still present before target motion onset in FTLD patients and 39 visually-guided pursuit was normal in both patient groups compared to controls. 40 Therefore, FTLD patients were only impaired when the predicted timing of an 41 external event was required to elicit an action. These results argue in favor of a role 42 of the frontal lobes in predictive movement timing. with motor neuron disease has a familial history (genetic assessment ongoing). 133
Twelve AD patients (three females) participated in the same experiment. They 134 were between 58 and 85 years old (M = 67.3 yrs, Std = 7.3 yrs). Diagnosis of AD 135 followed the NINCDS-ADRDA criteria (McKhann et al., 1984) . All AD patients 136 underwent neuropsychological assessment, structural and functional brain imaging. 137
In ten AD patients the diagnosis was corroborated by specific biomarkers 138 assessment: either a CSF analysis showing pathological levels of tau protein and/or 139 amyloid beta42 or a 18F-flutemetamol amyloid imaging PET scanner displaying 140 senile plaques in the brain (Vandenberghe et al., 2010) . The positivity of CSF and/or 141 imaging biomarkers in the AD patients supported the diagnosis in mild cases when 142 the MMSE was above the classical threshold of 24/30 (Jack et al., 2011). 143
All patients were followed-up by the same neurologist that made the diagnosis 144 initially (author AI) and were re-examined six months after the eye recording in order 145 to validate the diagnosis. The morphological and functional imaging deficits were 146 recorded by the same neurologist (AI) who was unaware of the oculomotor 147 performances of the patients. 148
Sixteen age-matched control subjects (four females) participated in the same 149 experiment as control (CTRL) subjects. They were between 55 and 83 years old (M = 150
yrs, Std = 4.3 yrs). 151
Data of one FTLD patient (from FTD subgroup), one AD patient and one CTRL 152 subject were excluded based on their abnormal visually-guided pursuit performance 153 (see "data analysis" part of the methods). We analyzed the data from thirteen FTLD 154 patients, eleven AD patients and fifteen CTRL subjects. The patient demographics as 155 well as their disease related characteristics are summed up in Table 1 
Stimuli 174
All trials started with an initial fixation during which a yellow dot (diameter of 175 0.8 deg) was visible on one side of horizontal meridian of the screen (between 25 176 and 15 deg of eccentricity) for 1000ms (Fig. 2) . The stimulus disappeared for 300 ms7 (gap period) and then immediately started to move toward the center at constant 178 velocity for 2000 ms. After 600 ms, the target transiently disappeared for 800 ms and 179 then reappeared for an additional 600 ms period (test trials). The direction (leftward 180 or rightward) and the velocity of the target (10, 15 or 20 deg/s) were kept constant 181 within a block but changed randomly across blocks. The duration of the block 182 (between 20 and 25 trials) was adjusted for each subject to reduce fatigue effects. In 183 order to minimize sequence effects, the order in which the blocks were received was 184 randomized across subjects. The subjects were instructed to follow the dot even 185 when it was blanked. Each subject or patient performed between 8 and 12 blocks. 186
So, there were at least 30 test trials per subject per target velocity. There was a 2 187 minute break between two consecutive blocks in order to keep the subjects alert and 188
concentrated. 189
During the first two trials as well as 3 other trials of each block, the target was 190 continuously visible (control trials) in order to reinforce the continuous movement of 191 the target. The visually guided smooth pursuit gain was measured in these trials. 192
Except the first two, the control trials were randomly inserted in the block but were 193 always followed by at least three test trials. Therefore, the test trials were divided into early (first three test trials, also identified 211 as P1) and late trials (remaining test trials). The late trials were further divided into 212 three periods P2 (first five of them), P3 (next five ones) and P4 (remaining trials: 213 between 5 and 10 trials). 214
In test trials, we measured the residual pursuit gain as the mean smooth 215 pursuit velocity averaged over a 50ms period centered at 500ms after target 216 disappearance, divided by target velocity. The same measure was extracted in 217 control trials as a proxy of the visually-guided smooth pursuit gain. All patients and 218 subjects had a visually-guided pursuit gain higher than 0.85, except three people 219 (one FTLD patient, one AD patient and one CTRL subject) that had a pursuit gain 220 lower than 0.6. These subjects were excluded from further analyses. 221
In test trials, the predictive smooth pursuit reacceleration was measured as the 222 slope of the linear fit for the smooth velocity trace between 100 ms before target 223 reappearance and 50 ms after this reappearance, i.e. before any influence of the 224 visual feedback. For the statistical analyses, data were collapsed across directions because 247 none of the studied parameters was influenced by the direction of target motion. 248 ANOVA was performed on intra-subject mean of the different parameters with group 249 as between-subject factor and velocity as within-subject factors. Tukey's Post Hoc 250 test was used to evaluate one-to-one differences. Statistical analyses were 251 performed with Statistica (Statsoft, Tulsa, OK). 252 253
Results
254
Visually-guided and predictive smooth pursuit 255
In control trials (target continuously visible), the performance of the smooth 256 pursuit response was comparable across groups (Fig. 3A, 
dashed traces). This 257
indicates that visually-guided pursuit was normal in FTLD and AD patients in early 258 course of the disease when compared to age-matched control subjects (ANOVA: 259 main effect of group on visually-guided smooth pursuit gain: F(2,36)=0.81, p=0.57). In 260 test trials, when the target was blanked, subjects continued to track the target with 261 the same eye velocity for another 100ms before it decreased exponentially towards a 262 plateau level. During the first three test trials of each block (early test trials), eye 263 velocity continued to decay slowly until 100ms after target reappearance, i.e. when 264 visual feedback of target motion became available and elicited a visually-guided 265 reacceleration (Fig. 3A , solid traces). In these trials, subjects from all groups 266 exhibited a similar behavior. 267
In the late test trials (all test trials except the first three, i.e. periods P2 to P4), 268 the decay in eye velocity was similar to the one observed during the early trials for all 269 Oculomotor performance was quantified by the measure of pursuit gain 500ms 277 into the blanking period in order to assess the decay in eye velocity and by the eye 278 acceleration at the end of the blanking period in order to assess the predictive 279 reacceleration. The between-group differences were analyzed over the course of the 280 block (periods P1 to P4, see Methods) and for the late trials only (P2 to P4 merged 281 together). 282
As illustrated in Fig. 4 , pursuit gain 500ms into the blanking period was very 283 similar across groups ( Fig. 4A ; ANOVA, main effect of group: F(2,144)=1.27 p=0.38) 284 and did not evolve over the course of the blocks (ANOVA, main effect of period: 285 F(3,144)=0.29 p=0.83). Moreover, there was no between-group difference in residual 286 velocity when it was measured from 400ms to 600ms. Comparison of the individual 287 data from all subjects (Fig. 4B) revealed that the residual pursuit gain was quite 288 variable across subjects but had a similar range for all three groups ( Inter-individual variability of reacceleration during all late trials was very low 313 within groups (Fig. 4D ). All subjects from the control group (N=15) exhibited a 314 positive reacceleration around the time of target reappearance. Only one from the AD 315 group (N=11) did not (patient AD2). Moreover, the excluded control subject and AD 316 patient also showed a predictive reacceleration. In contrast, only two of the FTLD 317 patients (N=13) showed signs of predictive reacceleration (patients FTLD6 and 318 FTLD2). The excluded FTLD patient did not reaccelerate predictively. There was no 319 difference in predictive reacceleration between the three FTLD subgroups. 320
Given the very small overlap in predictive reacceleration across groups, 321 the absence of predictive reacceleration could be considered as a potential 322 biomarker for FTLD. This biomarker has a sensitivity of 85% (=11/13). Its specificity 323 between CTRL and FTLD is 100% (=15/15) and between AD and FTLD is about 91% 324 (10/11). Sensitivity and specificity measures are improved if the subjects that were 325 excluded because of low visually-guided pursuit gain are included in the analysis. 326
Sensitivity becomes 86% (12/14). Specificity between CTRL and FTLD remains at 327 100%. Specificity between AD and FTLD increases to 92% (11/12). In contrast, the 328 neuropsychological data did not separate FTLD patients from AD patients as 329 accurately as the predictive reacceleration (Table S1 ). As expected, AD patients 330 were in general more amnesic but less impaired at language tests than FTLD 331 patients. However, the variability across patients was quite high. In addition, the 332 executive tests were comparable across the two groups of patients. 333
334
Insert Fig. 4 around here  335 
336
Predictive smooth pursuit before target motion onset 337
The absence of predictive reacceleration in the FTLD group could be due 338 either to the inability to elicit any predictive action or to the inability to know when the 339 target will reappear. Indeed, in absence of timing information, no predictive Interaction between saccades and pursuit 371
During blanking of the target, the amplitude of the saccades is adjusted to the 372 level of the eye velocity decay on a trial-to-trial basis (e.g. Fig. 6.A) . A difference in 373 modulation of the saccadic amplitude by the smooth pursuit performance across 374 populations would highlight a deficit in internal representation of target motion as this 375 modulation depends on where the target is during the blanking period. This 376 modulation is revealed by the strong correlation between the smooth eye 377 displacement (SED; how much smooth pursuit moved the eyes) and the saccadic 378 displacement (SAD; how much the saccades moved the eyes) during the blanking 379 period (see Methods). The SED is predominantly determined by the eye velocity 380 decay and not by the predictive reacceleration, which happened too late to largely 381 influence the smooth eye displacement. The correlation between SED and SAD is 382 illustrated for a typical FTLD patient in Fig. 6A . This plot shows that the inter-trial 383 variability of the smooth eye displacement during the blanking was quite high 384 (variability along the x-axis) but that the saccades largely compensated for this 385 variability. Indeed, in trials during which the smooth eye displacement was small, 386 saccadic displacement was large (Fig. 6A point #1) . In contrast, when the smooth 387 eye displacement was large, the saccadic displacement was reduced (Fig. 6A point  388   #2 ). In both cases, the synergy between saccades and pursuit allowed the eyes to be 389 close to the target at its reappearance (target position corresponds to the dashed 390 trace). To quantify the synergy between saccades and pursuit, the slope of the linear 391 fit performed on the SED-SAD relationship (solid trace) was used. Perfect synergy 392 would correspond to a slope of -1. In the experiment, the synergy between saccades 393 and pursuit did not differ across groups ( 
Discussion
403
In the present study, the smooth pursuit response of mild FTLD patients during 404 a visually-guided and a predictive tracking task was compared to the performance of 405 control subjects and mild Alzheimer's disease patients. All groups had normal 406 visually-guided pursuit responses. During the blanking, eye velocity dropped in all 407 groups to a "plateau level". After some practice, eye velocity increased before target 408 reappearance in control subjects and AD patients but failed to recover predictively in 409 However, the ability of eliciting anticipatory eye movements was still present in 434 FTLD patients as they were able to elicit them before target motion onset (i.e., during 435 the initial gap period). In this case, the disappearance of the fixation point could act 436 as a "go signal" for all subjects, which could help them to anticipate target motion 437 onset. In contrast, the long blanking period with the absence of go cue prevented 438 them to reaccelerate predictively. 439
Interestingly enough, this impairment is not present in mild AD patients, which 440 reflects the particular involvement of the frontal lobes in predictive reacceleration. and forgetting the wording. In contrast, our task was very sensitive to subtle deficits 498 present in early stage FTLD patients. 499
Based on predictive smooth pursuit measurements, we differentiated FTLD 500 patients from AD patients and controls. All of the 15 controls and 10 out of 11 of the 501 mild AD patients exhibited a predictive reacceleration before target reappearance 502 while only 2 out of the 13 FTLD patients were able to do so. This dramatic 503 impairment of mild FTLD patients on a very particular aspect of a smooth pursuit task 504 when compared to healthy controls and mild AD patients highlights the potential of 505 this oculomotor task in order to isolate a cheap and efficient biomarker for FTLD. 506 
